Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5–11 years old children with prior COVID-19-Reference-Cited by-同舟云学术

Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5–11 years old children with prior COVID-19

Published:2024-01 Issue:2 Volume:42 Page:263-270
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Di Chiara Costanza,Cantarutti Anna^ORCID,Raffaella Petrara Maria,Bonfante Francesco^ORCID,Benetti Elisa,Boracchini Riccardo^ORCID,Bosa Luca^ORCID,Carmona Francesco,Cosma Chiara,Cotugno Nicola^ORCID,Le Prevost Marthe,Martini Giorgia^ORCID,Meneghel Alessandra,Pagliari Matteo^ORCID,Palma Paolo^ORCID,Ruffoni Elena^ORCID,Zin Annachiara,De Rossi Anita,Giaquinto Carlo,Donà Daniele^ORCID,Padoan Andrea

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference34 articles.

1. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern;Goel;Science,2021

2. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination;Painter;Immunity,2021

3. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination;Goel;Sci Immunol,2021

4. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants;Bates;Sci Immunol,2022

5. Tejedor Vaquero S, de Campos-Mata L, Ramada JM, et al. The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity.Front Immunol. 2021;12:737083. Published 2021 Sep 3. doi:10.3389/fimmu.2021.737083.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years;Vaccine;2024-08

2. Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5–11 years with underlying diseases: A prospective observational study;Journal of Infection and Chemotherapy;2024-08